{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:36:17Z","timestamp":1791308177963,"version":"4.3.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.nucmedbio.2011.05.003","type":"journal-article","created":{"date-parts":[[2011,7,9]],"date-time":"2011-07-09T03:41:58Z","timestamp":1310182918000},"page":"1119-1127","source":"Crossref","is-referenced-by-count":28,"title":["Effect of chelator conjugation level and injection dose on tumor and organ uptake of 111In-labeled MORAb-009, an anti-mesothelin antibody"],"prefix":"10.1016","volume":"38","author":[{"given":"In Soo","family":"Shin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Myung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung Sub","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengsheng","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Regino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth T.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffit","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa F.","family":"Campo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Earl F.","family":"Albone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L.","family":"Choyke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Pastan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang H.","family":"Paik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2011.05.003_bb0005","first-page":"317","article-title":"Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments","volume":"68","author":"Carrasquillo","year":"1984","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.nucmedbio.2011.05.003_bb0010","first-page":"1447","article-title":"Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma","volume":"1","author":"Mulligan","year":"1995","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2011.05.003_bb0015","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1182\/blood.V86.11.4063.bloodjournal86114063","article-title":"Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac","volume":"86","author":"Waldmann","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.nucmedbio.2011.05.003_bb0020","first-page":"268","article-title":"Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution","volume":"40","author":"Carrasquillo","year":"1999","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2011.05.003_bb0025","first-page":"1720","article-title":"Imaging and phase I study of 111In- and 90Y-labeled anti-Lewis Y monoclonal antibody B3","volume":"6","author":"Pai-Scherf","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2011.05.003_bb0030","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","article-title":"Pivotal study of iodine I-131 tositumomab for chemotherapy\u2013refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas","volume":"19","author":"Kaminski","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2011.05.003_bb0035","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2011.05.003_bb0040","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.ijrobp.2006.06.038","article-title":"Cure of incurable lymphoma","volume":"66","author":"DeNardo","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.nucmedbio.2011.05.003_bb0045","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0883-2897(86)90003-6","article-title":"Chelating agents for the binding of metal ions to antibodies","volume":"13","author":"Meares","year":"1986","journal-title":"Int J Rad Appl Instrum B"},{"key":"10.1016\/j.nucmedbio.2011.05.003_bb0050","first-page":"2639","article-title":"Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity","volume":"49","author":"Kozak","year":"1989","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2011.05.003_bb0055","first-page":"473","article-title":"Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent","volume":"31","author":"Deshpande","year":"1990","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2011.05.003_bb0060","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/0969-8051(93)90096-D","article-title":"Evaluation of a new DTPA-derivative chelator: comparative biodistribution and imaging studies of 111In-labeled B3 monoclonal antibody in athymic mice bearing human epidermoid carcinoma xenografts","volume":"20","author":"Camera","year":"1993","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2011.05.003_bb0065","first-page":"882","article-title":"Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies","volume":"35","author":"Camera","year":"1994","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2011.05.003_bb0070","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1021\/bc00033a012","article-title":"Electrophoretic method for the quantitative determination of a benzyl-DTPA ligand in DTPA monoclonal antibody conjugates","volume":"6","author":"Pham","year":"1995","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2011.05.003_bb0075","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1021\/bc0000886","article-title":"An improved method for conjugating monoclonal antibodies with N-hydroxysulfosuccinimidyl DOTA","volume":"12","author":"Lewis","year":"2001","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2011.05.003_bb0080","first-page":"1158","article-title":"Factors influencing DTPA conjugation with antibodies by cyclic DTPA anhydride","volume":"24","author":"Paik","year":"1983","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2011.05.003_bb0085","first-page":"932","article-title":"Optimization of the DTPA mixed-anhydride reaction with antibodies at low concentration","volume":"24","author":"Paik","year":"1983","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2011.05.003_bb0090","first-page":"878","article-title":"Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates","volume":"55","author":"Kukis","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2011.05.003_bb0095","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.nucmedbio.2006.08.001","article-title":"Evaluation of 177Lu-DOTA-labeled aglycosylated monoclonal anti-L1-CAM antibody chCE7: influence of the number of chelators on the in vitro and in vivo properties","volume":"33","author":"Knogler","year":"2006","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2011.05.003_bb0100","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ijc.2910500308","article-title":"Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium","volume":"50","author":"Chang","year":"1992","journal-title":"Int J Cancer"},{"key":"10.1016\/j.nucmedbio.2011.05.003_bb0105","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1073\/pnas.93.1.136","article-title":"Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers","volume":"93","author":"Chang","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nucmedbio.2011.05.003_bb0110","first-page":"20","article-title":"Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin","volume":"7","author":"Hassan","year":"2007","journal-title":"Cancer Immun"},{"key":"10.1016\/j.nucmedbio.2011.05.003_bb0115","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1158\/1078-0432.CCR-10-2275","article-title":"Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin expressing cancers","volume":"16","author":"Hassan","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2011.05.003_bb0120","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/1078-0432.CCR-05-1477","article-title":"Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer","volume":"12","author":"Hassan","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2011.05.003_bb0125","doi-asserted-by":"crossref","first-page":"17099","DOI":"10.1073\/pnas.0708101104","article-title":"Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors","volume":"104","author":"Zhang","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.nucmedbio.2011.05.003_bb0130","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal Biochem"},{"key":"10.1016\/j.nucmedbio.2011.05.003_bb0135","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1021\/bc00016a014","article-title":"Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA-monoclonal antibody conjugates","volume":"3","author":"Pippin","year":"1992","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2011.05.003_bb0140","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/0076-6879(86)21067-8","article-title":"Determination of the true immunoreactive fraction of monoclonal antibodies after radiolabeling","volume":"121","author":"Lindmo","year":"1986","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.nucmedbio.2011.05.003_bb0145","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/(SICI)1097-0215(19990209)80:4<559::AID-IJC13>3.0.CO;2-Y","article-title":"111Indium labeled monoclonal antibody K1: biodistribution study in nude mice bearing a human carcinoma xenograft expressing mesothelin","volume":"80","author":"Hassan","year":"1999","journal-title":"Int J Cancer"},{"key":"10.1016\/j.nucmedbio.2011.05.003_bb0150","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.nucmedbio.2009.01.001","article-title":"A simplified suite of methods to evaluate chelator conjugation of antibodies: effects on hydrodynamic radius and biodistribution","volume":"36","author":"Al-Ejeh","year":"2009","journal-title":"Nucl Med Biol"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096980511100120X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096980511100120X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,21]],"date-time":"2020-06-21T06:33:02Z","timestamp":1592721182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096980511100120X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S096980511100120X"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2011.05.003","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}